Trial · Interventional
CompletedPhase 2Registry dataEvaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Overview
- Status
- Completed
- Phase
- Phase 2
- Enrollment
- Not stated
- Sponsor
- Palatin Technologies, Inc · Industry
- Design
- Randomized · Double masking
- Countries
1 country
United States
- Start
- Feb 2006
- Primary completion
- May 2007
- Completion
- May 2007
- First posted
- 22 Jan 2007 (estimated)
- Last update posted
- 23 Feb 2011 (estimated)
- Conditions
- Sexual Arousal Disorder
Timeline
1 trial · 1 completed
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 2
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
NCT00425256Feb 2006 to May 2007
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Interventions
- BremelanotideDrug
Arms0
The registry lists no arms for this trial.
Primary outcomes0
Outcomes the sponsor listed as primary.
The registry lists no primary outcome.
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
Completed trials do not always post results.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- Female
- Age
- from 21 Years up to 70 Years
- Healthy volunteers
- Not stated
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.